Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.15.1 (
ACE
)
18,300
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study is to assess the association of two polymorphisms, the
cartilage intermediate layer protein 2
(
CILP2
) G/T and
angiotensin converting enzyme
(
ACE
) I/D, with blood pressure and anthropometrical and biochemical parameters related to the development of cardiovascular disease. The entire study sample comprised 341 women ranging in age from 39 to 65 years. The
CILP2
genotypes were determined by PCR-RFLP and the
ACE
genotypes by PCR. The Bonferroni pairwise comparisons showed the effect of the
CILP2
genotype on high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), apoB-to-apoA1 ratio, the total cholesterol (TC)-to-HDL-C ratio, non-HDL-C, and the LDL-C-to-HDL-C ratio (P < 0.05). Here, higher mean levels of HDL-C and lower mean levels of the remaining above mentioned lipid parameters were registered in the GT/TT genotype carriers than in GG carriers. Statistically significant association was identified between the
ACE
genotype and the following parameters: TC, LDL-C, and non-HDL-C (P < 0.05). The II genotype can lower serum level of TC (B = 0.40), LDL-C (B = 0.37), and non-HDL-C levels. The results of this study suggest that the minor T allele of
CILP2
gene and I allele of
ACE
gene have a protective effect against elevated serum lipid and lipoprotein levels.
...
PMID:Association of CILP2 and ACE gene polymorphisms with cardiovascular risk factors in Slovak midlife women. 2435 Feb 79